Mankind Pharma Receives ESG Rating of '64.8' (Grade B) from SES
Mankind Pharma received an ESG Rating of '64.8' (Grade B) from SES ESG Research for FY 2024-25, based on publicly available data. The company did not commission the rating.
The ESG rating provides information about the company's sustainability practices but does not have a direct, immediate impact on its financials or operations.
The announcement is a disclosure of an ESG rating received by the company, which is neither inherently positive nor negative.
* Mankind Pharma has been assigned an Environmental, Social, and Governance (ESG) Rating of '64.8' (Grade B) (Adjusted) by SES ESG Research Private Limited. * The rating was assigned independently by SES for FY 2024-25 based on publicly available information. * Mankind Pharma did not engage SES for this rating.
What to do with a filing like this
Mankind Pharma Limited filed this with the NSE as a statutory disclosure, categorised under esg reports. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Mankind Pharma Limited. Read the original for the full detail.